



## Signals of T<sub>h</sub>2 immune response from COVID-19 patients requiring intensive care

Luca Roncati<sup>1</sup> · Vincenzo Nasillo<sup>1</sup> · Beatrice Lusenti<sup>1</sup> · Giovanni Riva<sup>1</sup>

Received: 18 April 2020 / Accepted: 27 April 2020 / Published online: 8 May 2020  
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Dear Editor,


Naïve T-helper cells (T<sub>h</sub>0) can respond to novel pathogens that the immune system has never encountered before, as is the specific case of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the positive-sense single-stranded RNA virus responsible for the ongoing pandemic named coronavirus disease 2019 (COVID-19). Depending on the infectious agent, T<sub>h</sub>0 polarize the immune response into T-helper type 1 (T<sub>h</sub>1), the default response in immunocompetent subjects to intracellular or phagocytosable pathogens (e.g. viruses, bacteria, protozoa, fungi) and mediated by macrophages and T-cytotoxic (T<sub>c</sub>) cells (*cell-mediated immunity*), or into T-helper type 2 (T<sub>h</sub>2), classically directed against extracellular non-phagocytosable pathogens, for instance helminths, and whose main effectors are eosinophils, basophils and mastocytes, as well as B cells (*humoral immunity*) [1]. Eosinophils play a direct role in fighting RNA viruses, as demonstrated by the presence of RNases inside their granules [1]; however, they have been negatively associated with the pathophysiology of the respiratory virus infections, since they trigger bronchoconstriction and dyspnea, besides virus-induced exacerbations of allergic airways diseases, by releasing a large amount of cationic proteins and cytokines, among which interleukin-6 (IL-6), a key mediator also for the development of the “cytokine storm” in COVID-19 fatal cases [2, 3]. At some extent, the smooth muscle cells in the tunica media of blood vessels can produce IL-6, too [4]. It belongs to T<sub>h</sub>2 cyto-

kines class together with IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25; contrariwise, IL-2, IL-12, interferon- $\gamma$  and tumor necrosis factor- $\alpha$  are the main T<sub>h</sub>1 cytokines, able to stimulate the inducible form of the nitric oxide (NO) synthase to produce NO free radicals endowed with virucidal activity [1]. To minimize the contagion risk in healthcare personnel, we have prepared and examined a limited number of 15 peripheral blood smears from a wider series of hospitalized COVID-19 patients, just admitted to intensive care and monitored through blood tests; in all the cases, we have found cytological signals of T<sub>h</sub>2 immune response, represented by eosinophilia plus basophilia, degranulated eosinophils, Türk cells or plasma cells, together with rouleaux and T<sub>c</sub> lymphopenia (Fig. 1). On the basis of our findings, for reasons still unclear, maybe related to the viral load, T<sub>h</sub>1 and T<sub>c</sub> breakdown, antigenic cross-reactivity or the type of antigen-presenting cell stimulating T<sub>h</sub>0, the immune system mounts a T<sub>h</sub>2 response against SARS-CoV-2 in patients requiring intensive care, rather than a T<sub>h</sub>1 response, which would keep the infection under control by means of macrophages and T<sub>c</sub> cells. This event is more likely in patients affected by cancer, immunodeficiency, autoimmune disorders, congestive heart failure, chronic obstructive pulmonary disease and hepatic cirrhosis, or in those who have suffered major surgery and traumatic injury, or who are on glucocorticoid therapy and total parenteral nutrition, all known conditions suppressive to T<sub>h</sub>1 immunity [1]. The mounting of a T<sub>h</sub>2 immune response allows to explain well the concurrent

✉ Luca Roncati  
emailmedical@gmail.com; roncati.luca@aou.mo.it

<sup>1</sup> Hemolymphopathology Team, University Hospital Modena, Modena, Italy

**Fig. 1** Cytological signals of  $T_H2$  immune response on peripheral blood smears from COVID-19 patients requiring intensive care: **a** on the right side of the panel, three eosinophils in a row accompanied by a basophile in the upper left corner ( $\times 40$  objective); **b** an eosinophil in the degranulation phase ( $\times 100$  objective); **c** a bilobed degranulated eosinophil in the center of the panel ( $\times 100$  objective); **d** an immature plasma cell (Türk cell) in the midst of prominent rouleaux ( $\times 100$  objective) (May-Grünwald stain)



gastrointestinal symptoms present up to 30% of COVID-19 patients and significantly associated with dyspnea [5]; in fact, hyperperistalsis and gastric fluid acidification are also two notorious default mechanisms of defense to expel parasites governed by  $T_H2$  cytokines [1].

### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** All procedures followed were in accordance with the ethical standards and with the Helsinki Declaration of 1975, as revised in 2008.

**Informed consent** Not applicable since the manuscript does not contain any patient data.

### References

1. Spellberg B, Edwards JE Jr (2001) Type 1 / type 2 immunity in infectious diseases. *Clin Infect Dis* 32(1):76–102
2. Rosenberg HF, Dyer KD, Domachowske JB (2009) Eosinophils and their interactions with respiratory virus pathogens. *Immunol Res* 43(1–3):128–137
3. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (2020) The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. *Int J Antimicrob Agents*:105954. <https://doi.org/10.1016/j.ijantimicag.2020.105954>
4. Song Y, Shen H, Schenten D, Shan P, Lee PJ, Goldstein DR (2012) Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 32(1):103–109
5. Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, Yang WB, Yang BH, Zhang JC, Ma WL, Wang XR, Zhou Q (2020) Clinical characteristics of SARS-CoV-2 infected pneumonia with diarrhea. *Lancet Respir Med SSRN*. <https://doi.org/10.2139/ssrn.3546120>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.